Grade My Investments
HomeFree Stock Grades › ANIK

Anika Therapeutics, Inc. (ANIK) Stock Grade

ANIK · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$137.8M
P/E Ratio
Revenue Growth (YoY)
-5.9%
Net Margin
-9.6%
Return on Equity
Dividend Yield
None

About Anika Therapeutics, Inc.'s fundamentals

Anika Therapeutics is a small-cap medical device company with a market capitalization of $137.8 million that is currently unprofitable, reporting a net loss and a negative net margin of -9.6% in its latest annual statement. The company is also experiencing revenue headwinds, with year-over-year revenue declining 5.9%. Despite the accounting losses, the company generated positive free cash flow, suggesting that operational cash generation remains intact despite current profitability challenges.

Track ANIK free — no credit card required. Live grade + monthly AI report →